Calquence 100 mg Capsule

Calquence 100 mg Capsule is a tyrosine kinase inhibitor or cancer growth inhibitor that is primarily used to treat people with mantle cell lymphoma (MCL) who have had at least one prior treatment for their malignancy (cancer), as well as adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Cancer is caused by a genetic mutation that causes our cells to divide uncontrollably and spread into neighbouring tissues.

Calquence 100 mg Capsule contains Acalabrutinib, a tyrosine kinase inhibitor. Tyrosine kinases are enzymes in the body that transmit signals to cells, telling them to grow and divide. Acalabrutinib inhibits these signals to cancer cells. Cells die when their signals are disrupted. This could help to slow the progression of the cancer.

To treat your condition effectually, continue using Calquence 100 mg Capsule for as long as your doctor has prescribed it. The most common adverse reactions are anaemia (lack of blood), neutropenia (low count of neutrophils), upper respiratory tract infection, thrombocytopenia (Low platelet level), headache, diarrhoea, and musculoskeletal pain. You should talk to your doctor if you persistently experience these side effects.

It is recommended not to use if you are hypersensitive to any component present in Calquence 100 mg Capsule and suffer from Severe Hepatic Impairment. Calquence 100 mg Capsule can cause fetal harm when administered to a pregnant woman. It is critical not to become pregnant or get pregnant while undergoing therapy and for several months after the treatment. Using effective contraceptive methods is recommended while on therapy with Calquence 100 mg Capsule. Contact your doctor immediately if you or your partner becomes pregnant while undergoing therapy. Breastfeeding is usually not advised during this treatment. Alcohol should be avoided during treatment with this medicine. Safety and effectiveness in children have not been established.

Calquence 100 mg Capsule is primarily used to treat people with mantle cell lymphoma (MCL) who have had at least one prior treatment for their malignancy, as well as adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Calquence 100 mg Capsule contains Acalabrutinib, a tyrosine kinase inhibitor. Tyrosine kinases are enzymes in the body that send signals to cells, directing them to grow and divide. Acalabrutinib blocks these signals to cancer cells. Cancer cells die when their signals are interrupted. This could help to delay the progression of the cancer.

Before taking the Calquence 100 mg Capsule, inform your doctor about all your medical conditions, sensitivities, and medications you are using. If you are a woman capable of having children, you should use an effective method of contraception during Acalabrutinib treatment and for at least one week after the last dose. If you are a man, you should use a barrier method of contraception to prevent your partner from becoming pregnant while taking Acalabrutinib and for at least one week after the last dose. Unless the doctor suggests, do not use any other medicine, including herbal or vitamin supplements.

• Keep all of your doctor's and laboratory appointments.
• Pregnancy testing is recommended prior to starting treatment with Calquence 100 mg Capsule.